About TECX

Founded: n/a
Employees: 60
CEO: Alise Reicin
WebsiteView website: tectonictx.com

Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company’s lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.

Recent TECX News & Updates

Announcement • Apr 26

Tectonic Therapeutic, Inc. Appoints Jessica Chutter to Board of Directors, Effective June 8, 2026

Tectonic Therapeutic, Inc. announced it has appointed Jessica Chutter to its Board of Directors, effective June 8, 2026. Ms. Chutter brings more than four decades of experience in global healthcare investment banking, with deep expertise advising biotechnology and pharmaceutical companies on strategic positioning, mergers and acquisitions, and capital markets execution. She is widely recognized as a pioneer in investment banking in the biotechnology sector and has served as a trusted advisor to CEOs and boards across the industry. Ms. Chutter spent her career at Morgan Stanley, where she served as Managing Director from 1998 to February 2026 and helped build its biotechnology investment banking practice. Most recently, she was Vice Chair of Healthcare Investment Banking from 2020 to February 2026 and Chair of Biotechnology Investment Banking from 2010 to February 2026. Earlier in her tenure, she served as Co-Head of Biotechnology Investment Banking and held various roles in healthcare investment banking. Over the course of her career, Ms. Chutter advised biotechnology and pharmaceutical companies on strategic and capital markets initiatives and was involved in approximately $80 billion in capital raising transactions and $85 billion in strategic transactions. Ms. Chutter currently serves on the Board of Directors of PTC Therapeutics. She is also on the Board of The Hospital for Sick Children and the Toronto Innovation Acceleration Partners, a not-for-profit organization focused on translating health science research into commercial opportunities. She holds an M.B.A. from Harvard Business School and a Bachelor of Arts in Commerce and Honors Economics from McGill University.

Recent updates

No updates

Tectonic Therapeutic, Inc. Stock Price

TECX Share Price Performance

TECX Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

Tectonic Therapeutic, Inc. Key Details

About TECX

Recent TECX News & Updates

Tectonic Therapeutics: Currently In A Catalyst Vacuum

Tectonic Therapeutic, Inc., Annual General Meeting, Jun 08, 2026

Tectonic Therapeutic, Inc. Appoints Jessica Chutter to Board of Directors, Effective June 8, 2026

Recent updates

Tectonic Therapeutic, Inc. Competitors

Tyra Biosciences

ADMA Biologics

Aurinia Pharmaceuticals

Bausch Health Companies